Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia.

Authors	Zachary Braunstein, Eric McLaughlin, Anjali Mishra, Jonathan E Brammer
Journal	Blood advances (Blood Adv) Vol. 6 Issue 8 Pg. 2685-2687 (04 26 2022) ISSN: 2473-9537 [Electronic] United States
PMID	34996100 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References	Immunosuppressive Agents Cyclophosphamide
Topics	Cyclophosphamide (adverse effects) Humans Immunosuppressive Agents Leukemia, Large Granular Lymphocytic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!